News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Prevention of mother-to-child transmission
Dolutegravir: need to consider all pros and cons before switching in pregnancy

A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.

Published
11 July 2018
From
HIV i-Base
Side-effects
Efavirenz does not increase the risk of suicidal thoughts or depression in Ugandan adults

Treatment with the antiretroviral drug efavirenz did not increase the risk of depressive symptoms or suicidal thoughts in adults living with HIV in Uganda when

Published
29 June 2018
By
Keith Alcorn
Starting treatment
Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART

Rilpivirine is better tolerated, less toxic and more durable than efavirenz when used as part of a first-line antiretroviral regimen, investigators from Italy report in

Published
28 June 2018
By
Michael Carter
Side-effects
No association found between efavirenz, suicide risk

Contrary to previous findings, individuals with HIV treated with efavirenz demonstrated no increased risk for suicidal ideation or depression, according to new research published in Annals of Internal Medicine.

Published
26 June 2018
From
Healio
Ageing and HIV
What is on the minds of PLHIV in Europe in terms of their long term health?

If they were to switch to different HIV medications, long term health and a low risk of long term side effects are by far the two most important aspects in the eyes of respondents living with HIV in Europe.

Published
25 June 2018
From
EATG
Side-effects
New contraindication against using darunavir/cobicistat during pregnancy

On 22 June 2018, Janssen issued a Dear Doctor letter (linked below) against using darunavir/cobicistat during pregnancy. This new contraindication is based on significantly reduced plasma levels of darunavir and cobicistat during the second and third trimesters of pregnancy. Darunavir can still be used during pregnancy, but only when boosted by ritonavir.

Published
25 June 2018
From
HIV i-Base
Cardiovascular disease
Cumulative Ritonavir-Boosted Darunavir Use May Be Associated With Increased CVD Risk

In patients infected with HIV, the cumulative use for ritonavir-boosted darunavir was associated with a progressively increasing risk for cardiovascular disease, according to research published in The Lancet HIV.

Published
11 June 2018
From
Infectious Disease Advisor
Side-effects
Integrase Inhibitors Are Well Tolerated

Those on Tybost-boosted Vitekta are more than twice as likely as those taking Tivicay to switch meds because of adverse health events.

Published
31 May 2018
From
Poz
Treatment guidelines
South Africa: Birth defects fears prompt warnings about new ARV

Despite the public concern globally, very little has been said about the impact of the safety warning about dolutegravir on South Africa, the country with the largest HIV treatment programme in the world. The National Department of Health had already planned to introduce a dolutegravir-based first line regimen to replace the existing regimen, hoping to switch the majority of patients starting from last month.

Published
29 May 2018
From
Health-e
Cardiovascular disease
What's the connection between HIV and high blood pressure?

People with HIV are more likely than people without the virus to have high blood pressure, in part because of treatments and repercussions of the condition itself, a new review of research shows.

Published
23 May 2018
From
American Heart Association News
← Prev1...34567...84Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.